Betamethasone_Dipropionate: profile and news

Topical therapies show promise for Psoriasis 06 Mar 2006
A combination of calcipotriene and betamethasone dipropionate, a vitamin D analogue and a potent corticosteroid, was recently approved by the FDA in an ... - News-Medical.net,

Taro Receives Tentative Approval for Augmented Betamethasone ... Jan 26, 2006
...tentative approval from the US Food and Drug Administration ("FDA") for its Abbreviated New Drug Application for Betamethasone Dipropionate Lotion (Augmented ... - Genetic Engineering News,

FDA Approves Taclonex (Calcipotriene/Betamethasone Dipropionate) ... Jan 10, 2006
Taclonex is a topical ointment containing a combination of calcipotriene 0.005% and betamethasone dipropionate 0.064% for the treatment of psoriasis vulgaris ... - DG News

Taro tentatively OK'd for Diprolene Jan 26, 2006
The company said the Food and Drug Administration approved Taro's generic version of Schering's augmented betamethasone dipropionate lotion, 0.05 percent. ... - United Press International

Burbs: Atlas Air CEO to step down Jan 31, 2006
...of Hawthorne has received tentative approval from the US Food and Drug Administration for its new drug application for Betamethasone Dipropionate Lotion. ... - The Journal News.com,

FDA Approves Taclonex(R) - Once Daily Therapy for Treatment of ... Jan 10, 2006
Taclonex(R) is a topical ointment containing a combination of calcipotriene 0.005% and betamethasone dipropionate 0.064% for the treatment of psoriasis ... - PR Newswire (press release),

Warner Chilcott Reports Results for the Quarter and Nine Months ... Nov 11, 2005
...said "On July 1st we realigned our sales forces in anticipation of the expected launch of DOVOBET(R) (calcipotriol / betamethasone dipropionate) for psoriasis. ... - PR Newswire (press release),

Enters into co-promotion agreement with Bristol-Myers Squibb for ... Oct 3, 2005
Development Agreement with LEO Pharma to develop Dovobet®, LEO Pharma’s combination product containing calcipotriene and betamethasone dipropionate, for the ... - Biotechnology Investment Today (Press Release),

Two-Drug Topical Treatment Effective in Early Mycosis Fungoides Sep 28, 2005
Study Group of Cutaneous Lymphomas examined the effects of twice-weekly application of mechlorethamine hydrochloride and betamethasone dipropionate cream in 63 ... - Cancerpage.com,

NPPA FIXES/REVISES THE PRICES OF 308 FORMULATION PACKS Sep 19, 2005
It also includes 81 cases of Betamethasone Dipropionate and certain others formulations, formulated namely by M/s. Cipla, Sun Pharma, Wockhardt, Alkem and USV ... - Press Information Bureau (press release),

Fougera extends Line with Introduction of Clotrimazole & ... Jul 13, 2005
NY, July 13 /PRNewswire/ -- Today, the specialty pharmaceutical manufacturer Fougera released FDA approved Clotrimazole & Betamethasone Dipropionate Lotion USP ... - Yahoo News (press release)

Fougera extends Line with Introduction of Clotrimazole & ... Jul 13, 2005
13, 2005 /PRNewswire/ -- Today, the specialty pharmaceutical manufacturer Fougera released FDA approved Clotrimazole & Betamethasone Dipropionate Lotion USP 1 ... - PharmaLive.com (press release)

Taro Reports 4th Quarter and Full Year 2004 Results Feb 24, 2005
...quarter, Taro received final Abbreviated New Drug Application ("ANDA") approvals for five topical products: betamethasone dipropionate ointment (augmented ... - Business Wire (press release),

Other information

Indication
For relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses

Pharmacology
Betamethasone and its derivatives, betamethasone sodium phosphate and betamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties, betamethasone is combined with a mineralocorticoid to manage adrenal insufficiency and is used in the form of betamethasone benzoate, betamethasone dipropionate, or betamethasone valerate for the treatment of inflammation due to corticosteroid-responsive dermatoses. Betamethasone and clotrimazole are used together to treat cutaneous tinea infections.

Mechanism Of Action
Betamethasone is a glucocorticoid Receptor Agonist. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Betamethasone binds to plasma transcortin, and it becomes active when it is not bound to transcortin.

Drug Category
Corticosteroid; Glucocorticoids; Anti-inflammatory, steroidal; Immunosuppressant; ATC:A07EA04; ATC:C05AA05; ATC:D07AC01; ATC:D07XC01; ATC:H02AB01; ATC:R01AD06; ATC:R03BA04; ATC:S01BA06; ATC:S01CB04; ATC:S02BA07; ATC:S03BA03

Brand Names/Synonyms
Alphatrex; Bebate; Becort; Bedifos; Beta-Methasone; Beta-Methasone Alcohol; Beta-Val; Betacorlan; Betacortril; Betaderm; Betadexamethasone; Betafluorene; Betamamallet; Betametasona [Inn-Spanish]; Betametasone [Dcit]; Betamethasone; Betamethasone Alcohol; Betamethasone Base; Betamethasone Cream; Betamethasone Dipropionate; Betamethasone Sodium Phosphate; Betamethasone Valearate; Betamethasone Valerate; Betamethasone [Usan:Ban:Inn:Jan]; Betamethasonum [Inn-Latin]; Betamethasonvalerat Mikron.; Betamethazone; Betapredol; Betasolon; Betatrex; Betnelan; Betsolan; Celestene; Celestone; Celestone Syrup and Tablets; Cidoten; Dermabet; Desacort-Beta; Diproderm; Diprolene; Diprolene Af; Diprosone; Flubenisolone; HSDB 3015; Hormezon; Lotrisone; Luxiq; Luxiqo; Maxivate; Methazon; Rinderon; Rinderon A; Sch 4831; Uticort; Valisone; Valnac; Visubeta

Dosage Forms
Syrup; Tablet

Absorption
Minimal if applied topically

Interactions
Interactions for Betamethasone:
APRD00513_IN,txt

Chemical IUPAC Name
9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one

Chemical Formula
C22H29FO5

Half Life
5.6 hours

Drug Type
Approved Drug

# Accession No
APRD00513

CAS Registry Number
378-44-9